A High-Performance Liquid Chromatographic Assay for the Determination of Amphotericin B Serum Concentrations After the Administration of AmBisome, a Liposomal Amphotericin B Formulation
- 1 October 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 18 (5) , 604-609
- https://doi.org/10.1097/00007691-199610000-00014
Abstract
A sensitive and selective high-performance liquid chromatographic (HPLC) method has been developed for the determination of amphotericin B in human serum. After methanol deproteinization, amphotericin B and 3-nitrophenol (internal standard) are separated by reversed-phase chromatography and detected by ultraviolet absorbance. The analysis of human serum after the standard addition of amphotericin B (0.05-200.0 micrograms/mL) demonstrated excellent precision and accuracy over a five-day period. The HPLC assay uses two standard curve ranges. The high sensitivity curve range for low AmBisome dosage (1.0 mg/kg) is 0.05-20.0 micrograms/mL (curve 1), and the second curve range for the higher AmBisome dose regimens (2.5-5.0 mg/kg) is 0.5-200 micrograms/mL (curve 2). The intraday and interday coefficients of variations for standard curve 1 were 0.5-4.6% and 3.0-11.5%, respectively. The limit of quantitation was 0.05 microgram/mL. The intraday and interday coefficients of variation for standard curve 2 were 2.0-3.6 and 6.9-10.1, respectively. No interfering peak at the retention time for Amphotericin B and the internal standard were present in blank serums or serum samples spiked with fifteen potential co-administrated drugs with Amphotericin B treatment. The method was used to quantitate serum concentrations of amphotericin B in patients after the administration of AmBisome, a liposomal formulation of amphotericin B.Keywords
This publication has 18 references indexed in Scilit:
- Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single‐centre experience of 133 episodes in 116 patientsBritish Journal of Haematology, 1994
- Stability and mode of action of AmBisome® (liposomal amphotericin B)Journal of Controlled Release, 1994
- Amphotericin B and its delivery by liposomal and lipid formulationsJournal of Clinical Pharmacy & Therapeutics, 1993
- Liposomal Drug DeliveryClinical Pharmacokinetics, 1991
- Amphotericin B: delivery systemsAntimicrobial Agents and Chemotherapy, 1990
- Amphotericin B: current understanding of mechanisms of actionAntimicrobial Agents and Chemotherapy, 1990
- High-performance liquid chromatographic determination of amphotericin B in human serumJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidiasis in miceAntimicrobial Agents and Chemotherapy, 1984
- A Review of Complications of Amphotericin-B Therapy: Recommendations for Prevention and ManagementDrug Intelligence & Clinical Pharmacy, 1980
- Pharmacology, toxicity, and therapeutic usefulness of amphotericin BJAMA, 1966